Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Grünenthal Group Mexico Brazil Colombia Germany Chile

Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
Instagram: grunenthal

For further information, please contact:

Maren Thurow
Head Global Communication

Grünenthal GmbH
52099 Aachen

E-Mail: [e-mail]
Phone: [phone]

[1] In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.

 

View original content:https://www.prnewswire.co.uk/news-releases/grunenthal-announces-acquisition-of-the-rights-to-cialis-from-lilly-in-mexico-brazil--colombia-302470601.html